The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction

Published on Jul 11, 2017in Cardiovascular Diabetology9.951
· DOI :10.1186/S12933-017-0572-0
Mei-Tzu Wang2
Estimated H-index: 2
 , Lin Sheng-Che1
Estimated H-index: 1
 + 7 AuthorsWei-Chun Huang9
Estimated H-index: 9
Sources
Abstract
Background Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular outcomes. This study aimed to evaluate the impact of DPP-4 inhibitors on the survival of diabetic patients after first acute myocardial infarction (AMI).
Figures & Tables
Download
📖 Papers frequently viewed together
201391.25The New England Journal of Medicine
18 Authors (Benjamin M. Scirica, ..., Itamar Raz)
201591.25The New England Journal of Medicine
19 Authors (Jennifer B. Green, ..., Rury R. Holman)
20164.06American Journal of Translational Research
6 Authors (Saumya Reddy Kankanala, ..., Jixin Zhong)
References43
Newest
Apr 1, 2017·Diabetes Care19.11
#1M. Angelyn Bethel (University of Oxford)H-Index: 17
#2Samuel S. Engel (MSD: Merck & Co.)H-Index: 40
Last. Rury R. Holman (University of Oxford)H-Index: 118
view all 12 authors...
OBJECTIVE Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin on a primary composite outcome of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or unstable angina hospitalizations in patients with type 2 diabetes (HbA1c ≥6.5% [48 mmol/mol] and ≤8.0% ...
Source
Mar 1, 2017·Heart5.99
#1Shuo-Ming Ou (Taipei Veterans General Hospital)H-Index: 19
#2Hung Ta Chen (NYMU: National Yang-Ming University)H-Index: 3
Last. Yung-Tai Chen (NYMU: National Yang-Ming University)H-Index: 21
view all 6 authors...
Background Although recent clinical trials raised concerns about the risk for heart failure (HF) in dipeptidyl peptidase-4 (DPP-4) inhibitor use, data on the cardiovascular risks in the patients with pre-existing HF are still lacking. Methods We used Taiwan9s National Health Insurance Research Database to identify 196 986 patients diagnosed with type 2 diabetes mellitus (T2DM) who had previous history of HF between 2009 and 2013. This population included 30 204 DPP-4 inhibitor users and 166 782 ...
Source
Nov 15, 2016·International Journal of Cardiology4.16
#1Shingo KatoH-Index: 33
#2Kazuki FukuiH-Index: 15
Last. Kazuo KimuraH-Index: 61
view all 10 authors...
Abstract Background The present study determined whether dipeptidyl peptidase-4 (DPP-4) inhibition by alogliptin improves coronary flow reserve (CFR) and left ventricular election fraction (LVEF) in patients with type 2 DM and CAD. Materials and methods Twenty patients with type 2 DM and known or suspected CAD were randomly allocated to receive diet therapy plus alogliptin (n=10; mean age, 73.3±6.6y) or a control group given diet therapy and glimepiride (n=10; mean age, 76.7±7.3y). Breath-hold P...
Source
Nov 4, 2016·Cardiovascular Diabetology9.95
#1Satoshi IdaH-Index: 9
#2Kazuya MurataH-Index: 9
Last. Hiroka TakahashiH-Index: 4
view all 11 authors...
Background Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicato...
Source
Sep 13, 2016·Cardiovascular Diabetology9.95
#1Tatsuya Maruhashi (Hiroshima University)H-Index: 23
#2Yukihito Higashi (Hiroshima University)H-Index: 72
Last. Koichi Node (Saga University)H-Index: 59
view all 17 authors...
Background As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes.
Source
Sep 1, 2016·Cardiovascular Diabetology9.95
#1Chien Yi HsuH-Index: 16
#2Yu Wen Su (NYMU: National Yang-Ming University)H-Index: 5
Last. Shing-Jong LinH-Index: 72
view all 9 authors...
Background Pleiotropic effects on cardiovascular protection have been suggested in several oral antidiabetic drugs (OAD). The impacts of OADs on aortic aneurysm (AA) growth have been found in animal studies, but the evidence of their beneficial effects for AA protection in human are lacking. We investigated the relationship between OAD therapy and the risk of developing AA.
Source
Jul 1, 2016·Diabetes Research and Clinical Practice5.60
#1Jan W. Eriksson (Uppsala University)H-Index: 49
#2Johan Bodegard (AstraZeneca)H-Index: 26
Last. Anna Norhammar (KI: Karolinska Institutet)H-Index: 36
view all 6 authors...
Aims: There are safety concerns related to sulphonylurea treatment. The objective of this nationwide study was to compare the risk of cardiovascular disease (CVD), all-cause mortality and severe hy ...
Source
Mar 31, 2016·Journal of Diabetes Investigation4.23
#1Tsutomu Hirano (Showa University)H-Index: 52
#2Yusaku Mori (Showa University)H-Index: 1
We reported that native incretins, liraglutide and dipeptidyl peptidase‐4 inhibitors (DPP‐4i) all confer an anti‐atherosclerotic effect in apolipoprotein E‐null (Apoe −/−) mice. We confirmed the anti‐atherogenic property of incretin‐related agents in the mouse wire injury model, in which the neointimal formation in the femoral artery is remarkably suppressed. Furthermore, we showed that DPP‐4i substantially suppresses plaque formation in coronary arteries with a marked reduction in the accumulat...
Source
Mar 31, 2016·Cardiovascular Diabetology9.95
#1Takashi Nakamura (Kindai University)H-Index: 4
#2Yoshitaka Iwanaga (Kindai University)H-Index: 31
Last. Shunichi Miyazaki (Kindai University)H-Index: 48
view all 6 authors...
Background Gliptins should have beneficial effects beyond glycemic control, potentially on the pathophysiology of cardiovascular (CV) diseases, with some basic studies demonstrating this possibility. However, we are yet to answer whether there are any direct CV effects in the clinical setting. We aimed to examine the beneficial effects of sitagliptin in Japanese patients with diabetes and high CV risk for 12 months.
Source
Mar 1, 2016·Cardiovascular Diabetology9.95
#1Huang Tz Ou (NCKU: National Cheng Kung University)H-Index: 15
#2Kai Cheng Chang (NCKU: National Cheng Kung University)H-Index: 9
Last. Jin Shang Wu (NCKU: National Cheng Kung University)H-Index: 30
view all 4 authors...
Background Several antidiabetic drugs (i.e., sulfonylureas; SU, rosiglitazone) have been reported to be associated with increased risks of cardiovascular diseases (CVD) in patients with type 2 diabetes mellitus (T2DM). Dipeptidyl peptidase-4 inhibitors (DPP4i) are newly available antidiabetic drugs. Most studies only compared DPP4i with a placebo or SU, or targeted a specific CVD event of interest (i.e., heart failure; HF). Comparative research of CVD risks of DPP4i with other antidiabetic drugs...
Source
12345
Cited By25
Newest
Objectives: To investigate the application of tirofiban in patients with acute myocardial infarction complicated with diabetes and undergoing emergency interventional therapy. Methods: Two hundred patients with acute ST-segment elevation myocardial infarction (STEMI) complicated with diabetes who underwent percutaneous coronary intervention (PCI) and found to have high thrombus burden in coronary artery admitted to our hospital from September 2018 to September 2020 were selected as subjects, and...
Source
Oct 14, 2021·Endocrinology and Metabolism4.01
#1Inha Jung (SKKU: Sungkyunkwan University)H-Index: 2
#2Hyemi Kwon (SKKU: Sungkyunkwan University)H-Index: 18
Last. Won Young Lee (SKKU: Sungkyunkwan University)H-Index: 63
view all 7 authors...
BACKGROUND Patients with diabetes have a higher risk of requiring repeated percutaneous coronary intervention (PCI) than non-diabetic patients. We aimed to evaluate and compare the effects of anti-diabetic drugs on the secondary prevention of myocardial infarction among type 2 diabetes mellitus patients. METHODS We analyzed the general health check-up dataset and claims data of the Korean National Health Insurance Service of 199,714 participants (age ≥30 years) who underwent PCIs between 2010 an...
Source
Sep 12, 2021·Cardiovascular Therapy and Prevention
#1M. G. Chashchin (MSMU: I.M. Sechenov First Moscow State Medical University)
#2A. Yu. Gorshkov
Last. Oxana M. Drapkina
view all 3 authors...
Source
Sep 8, 2021·Cardiovascular Diabetology9.95
#1Shih-Hsiang Ou (KMU: Kaohsiung Medical University)
#2Hsin-Yu Chen
Last. Jin-Shuen ChenH-Index: 3
view all 6 authors...
BACKGROUND Type 2 diabetes mellitus is common in patients undergoing dialysis. However, the association between anti-diabetic drug use and survival outcomes is rarely discussed. We aimed to investigate whether continued anti-diabetic medication use affects the survival of diabetic dialysis patients and whether different hypoglycemic drug use influences prognosis. METHODS Using a nationwide database, we enrolled patients with incident end-stage renal disease under maintenance dialysis during 2011...
Source
Vascular aging is characterized by alterations in the constitutive properties and biological functions of blood vessel wall. Endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are indispensability elements in the inner layer and the medial layer of blood vessel wall respectively. Dipeptidyl peptidase 4 (DPP4) inhibitors, as a hypoglycemic agent, play a protective role in reversing vascular aging regardless of their effects in meliorating glycemic control in humans and animal models...
Source
Apr 1, 2021·Clinical and Experimental Pharmacology and Physiology2.56
#1Jovana Bradic (University of Kragujevac)H-Index: 6
#2Isidora Milosavljevic (University of Kragujevac)H-Index: 4
Last. Vladimir Jakovljevic (University of Kragujevac)H-Index: 19
view all 12 authors...
The aim of our study was to assess and compare the effects of dipeptidyl peptidase 4 (DPP4) inhibitors, saxagliptin and sitagliptin, on metabolic control of disease and cardiac function in rats with diabetes mellitus type 2 (T2DM). This research would provide novel understanding into the potentially protective effects of DPP4 inhibitors in helping salvage of the heart exposed to ischaemia-reperfusion (I-R) injury. Forty-eight Wistar albino rats were randomly divided into four groups: CTRL, Contr...
Source
Mar 5, 2021·Heart Rhythm6.34
#1Wence Shi (PKU: Peking University)H-Index: 1
#2Wenchang Zhang (PKU: Peking University)H-Index: 1
Last. Chunhua Ding (PKU: Peking University)H-Index: 8
view all 8 authors...
Abstract Background Diabetes is associated with the progression of atrial fibrillation (AF) and atrial flutter (AFL). However, whether glucose-lowering agents could reduce AF/AFL remains unclear. We hypothesized that different glucose-lowering agents exhibit different characteristic effects on the risk of AF/AFL. Objective To evaluate the effect of different glucose-lowering agents and identify the optimal treatment that can reduce AF/AFL events in patients with diabetes. Methods We searched Pub...
Source
Warfarin is an alternate choice for patients who are not eligible for non-vitamin K oral anticoagulants after acute myocardial infarction (AMI). This study aimed to compare the long-term outcome of triple antithrombotic therapy (TAT) with that of dual antiplatelet therapy (DAPT) after AMI. This was a nationwide, propensity score-matched, case–control study of 186,112 first AMI patients, of whom 2,825 received TAT comprising aspirin, clopidogrel, and warfarin. Propensity score matching in a ratio...
Source
Mar 1, 2021·Heart Failure Reviews4.21
#1Marina Rankovic (University of Kragujevac)H-Index: 2
#2Nevena Jeremic (University of Kragujevac)H-Index: 10
Last. Vladimir Jakovljevic (University of Kragujevac)H-Index: 19
view all 9 authors...
Previous studies have demonstrated that individuals with type 2 diabetes mellitus (T2DM) have a two- to fourfold propensity to develop cardiovascular disease (CVD) than nondiabetic population, making CVD a major cause of death and disability among people with T2DM. The present treatment options for management of diabetes propose the earlier and more frequent use of new antidiabetic drugs that could control hyperglycaemia and reduce the risk of cardiovascular events. Findings from basic and clini...
Source
Jun 24, 2020·Archives of Gynecology and Obstetrics2.34
#1Swapna Siddamalla (Osmania University)H-Index: 2
#2Suresh Govatati (Osmania University)H-Index: 14
Last. Manjula Bhanoori (Osmania University)H-Index: 18
view all 7 authors...
PURPOSE The purpose of the study was to investigate the association between gene phosphate and tensin homolog (PTEN) single nucleotide polymorphisms (SNPs) and risk of developing polycystic ovary syndrome (PCOS) in South Indian women. PTEN is one of the most important tumor suppressor genes that regulate cell proliferation, migration, and death. It is also involved in the maintenance of genome stability. PCOS is one of the most common endocrine disorders among women of reproductive age. It is a ...
Source
123
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.